Auneripharm SRL
1.6 FTEAuneripharm reported total assets of 359,664 € at the end of the 2025 financial year (annual accounts filed with the NBB on 08 May 2026), with 1.6 full-time equivalent.
The score of Auneripharm shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Accounts of the company itself (not consolidated).
The full file covers 2 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Auneripharm's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 08 May 2026
- Year ended 31 Dec 2024filed on 09 Jul 2025
Auneripharm's financial analysis
- Solvency43.8%sector median: 50.7%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Auneripharm
Auneripharm's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 1002.796.292
- VAT number
- BE1002796292
- Peppol
- Registered · 0208:1002796292 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 29 Nov 2023
- Registered office
- 1050 Brussels
- Size
- Micro · 1.6 FTE
- Latest accounts
- 2025 · filed on 08 May 2026
- Activity
- Business and other management consultancy activities (NACE 70200)
Auneripharm (SRL) has been based in Brussels since 2023, active in: business and other management consultancy activities. For 2025, it reports a net profit of 92,126 € and equity of 157,451 €; its revenue is not published. With 1.6 full-time equivalents, it is a micro-enterprise by headcount. Its solvency stands at 43.8%, below the median of its sector (50.7%).
Companies similar to Auneripharm
Companies in the same business, of comparable size and area, outside its group.
- Management Group Intercontinental Business and other management consultancy activities Antwerp · balance sheet 62,068 €
- Straightforward Solutions Business and other management consultancy activities Merelbeke-Melle · balance sheet 359,601 €
- G04 Solutions Business and other management consultancy activities Villers-le-Bouillet · balance sheet 359,593 €
- BEN Business and other management consultancy activities Herstal · balance sheet 359,802 €
- The Next Big Idea Business and other management consultancy activities Ghent · balance sheet 359,826 €
- Pascal Deflandre Management Business and other management consultancy activities Esneux · balance sheet 359,875 €
- Togoban Business and other management consultancy activities Kampenhout · balance sheet 359,451 €
- JN Invest Business and other management consultancy activities Wemmel · balance sheet 359,442 €
Frequently asked questions about Auneripharm
What is the revenue of Auneripharm?
Auneripharm files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Auneripharm?
In Belgium, the VAT number is the company number prefixed with BE: BE1002796292 for Auneripharm, if the company is VAT-registered. Its company number (CBE) is 1002.796.292.
Where is the registered office of Auneripharm?
According to the CBE register, the registered office of Auneripharm is in 1050 Brussels.
What is the equity of Auneripharm?
At the close of the 2025 financial year, the equity of Auneripharm amounts to 157,451 €, a solvency of 43.8% of total assets.
How many people work at Auneripharm?
1.6 full-time equivalents on average according to the 2025 social balance sheet.
Who manages Auneripharm?
The register lists 3 active mandates at Auneripharm. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Auneripharm
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →